Advertisement LTS Lohmann Therapie Systeme - Pharmaceutical Business review - Oral Thin Films
Pharmaceutical Business review is using cookies

ContinueLearn More

LTS Lohmann Therapie Systeme


LTS Lohmann Therapie Systeme

LTS provides alternative drug delivery systems in the form of transdermal therapeutic systems (TTS) and oral thin films (OTF).

The company develops and manufactures drug delivery systems that offer patients reliable therapeutic efficacy with total comfort and convenience.

Alternative drug delivery systems

LTS’ research and development (R&D) focuses on new technologies to complement and expand the potential of alternative drug delivery systems. It is continually developing its TTSs and OTFs, as well as microneedle technologies.

B2B pharmaceutical partner

As a business-to-business (B2B) partner to the pharmaceutical industry, the company offers solutions at all stages of drug development. On behalf of its partners, LTS develops and manufactures TTS and OTF.

LTS’ innovative transdermal systems include injection-free and microneedle units.

The company does not sell any of its own-branded products, making it a dedicated technology partner to the pharmaceutical industry, rather than a competitor against classical pharmaceutical companies. In addition, LTS does not develop any of its own active substances. Instead, it focuses its expertise on the development of new, innovative drug delivery systems that specialise in the transdermal application of existing and novel agents.

Based on a successful feasibility study, LTS develops the ideal delivery system for each customer and each substance.

Patches and oral wafers

LTS produces patches and oral wafers in any batch size for all global markets, offering a comprehensive full service, including packaging development and support in the drug approval process as required.

Complementing its full-service approach, LTS also takes on subsidiary tasks such as production as a contract manufacturer.

Drug delivery manufacturing partner

To achieve success in TTS and OTF, you need a strong, experienced and committed pharmaceutical partner at your side. As a market leader, LTS fulfils all these requirements.

The company has developed a wide variety of TTS products in the market, and its transdermal patches make treatment much easier for a large number of patients.

LTS has the experience and expertise to develop and manufacture successful products right up to market approval. LTS has sufficient capacity to manufacture the batch sizes required for global sales and high-volume products.

Two identical production facilities in Germany and the US secure supply chain reliability even in crisis periods. The company also has production capabilities of varying sizes to operate all demands, from early drug development to large-scale production campaigns.

LTS is recognised by all major health authorities worldwide and has broad experience in the field of hormone therapy and anaesthetics narcotic substances. It systematically separates the production of hormone products from non-hormone products to avoid any risk of possible cross-contamination.

LTS supports each client with a development team that can be integrated into the clients’ research teams. LTS provides customers with total transparency in all project phases.

LTS as a partner for healthcare innovations

LTS covers all the relevant technical steps in drug development, from feasibility studies to market launch and subsequent large-scale manufacturing. LTS manufactures for the global markets of your choice, making use of our expertise as an innovative market leader.


LTS Lohmann Therapie-Systeme AG
Lohmannstraße 2
D-56626 Andernach

Phone: (0 26 32) 99-0
Fax: (0 26 32) 99 22 00
Website: Micro Array Patches technology

LTS – Your Partner for Innovative Solutions

The development of new pharmaceutical drugs is a lengthy and complex process where not every highly promising active substance eventually becomes a successful drug. This is often because developers only think to develop tablets, capsules or solutions, but LTS offers an alternative: innovative approaches. With its transdermal therapeutic system (TTS) and oral thin films (OTF),…

Innovative Transdermal Technologies from LTS

LTS’s research and development (R&D) focuses on two new technologies to complement and expand the potential of alternative drug delivery systems. In addition to the permanent further development of LTS transdermal therapeutic systems (TTS) and LTS oral thin film (OTF) technologies, the company also develops innovative microneedle and the active LTS TTS technology. Passive patches…

Oral Thin Films for Drug Delivery

Oral thin films (OTF) are loaded with active substances that are used for drug delivery. They are taken orally and dissolve immediately in the mouth or are applied to the mucosa. For transmucosal films, the active substance enters the bloodstream directly via the oral mucosa, without having to first pass through the gastrointestinal tract. LTS…

Drug Delivery via Transdermal Therapeutic Systems

Transdermal patches or transdermal therapeutic systems (TTS) are drug delivery systems that are applied directly to the skin. The active substance is absorbed by the skin and is distributed through the body transdermally via the bloodstream. This unique mode of administration has improved the simplicity of treatment for patients for almost 30 years. The wide…
Quick Contact LTS Lohmann Therapie Systeme

LTS Sponsors Microarray Patch Systems Webinar

Painless self-administration by the patient has the potential to be the lowest risk, lowest cost and most preferred option for...
1st September 2020

German Health Authorities Grant LTS the Manufacturer’s Authorisation for Capsules

In September, the German health authorities extended the manufacturer’s authorisation for LTS Lohmann Therapie-Systeme AG (LTS) to include capsules.
12th December 2019

New TTS Webinar Open for Registrations

Our new webinar 'Transdermal Therapeutic Systems – Still an attractive technology?!' held by Dr Marco Emgenbroich on Nov. 26 at...
11th November 2019

LTS Donates Fire Truck to Zichow Fire Brigade

The 25-year-old former fire truck of the LTS plant fire brigade is fully functional and still in good condition.
22nd July 2019

Changes in the Supervisory Board of the LTS AG

The members of the supervisory board of the LTS AG have been newly elected. On June 28 2019, the shareholders...
1st July 2019

LEO Pharma and LTS Initiate Clinical Trial of Microarray Patches

LTS and LEO Pharma have announced that the companies will begin a clinical trial to test microarray patches that are...
19th March 2019

EsoCap Announces Kick-Off of an Industrial Development Collaboration with LTS

EsoCap and LTS Lohmann Therapy-Systeme (LTS) announced the start of cooperation on industrial development of a unique drug delivery technology...
20th February 2019

LTS AG Donates Pediatric Anaesthesia Trolley to St Nikolaus-Stifts Hospital

Lohmann Therapy System (LTS) is pleased to announce that its donation to the Association of Friends and Sponsors of the...
4th February 2019

New LTS Webinar

Pharmaceutical technology company LTS has announced that its new webinar 'Oral Thin Films – Tailoring Therapy Need' will be presented...
30th October 2018

Intec Pharma and LTS to manufacture Accordion Pill™

Formulation and film technology manufacturer LTS has announced it will be partnering with Intec Pharma to establish commercial-scale production capabilities...
12th March 2018

LTS to Present at the JP Morgan 36th Annual Healthcare Conference

LTS has announced that its CMO and member of the LTS management board Dr Tim G Schlange will present at the...
3rd January 2018

E Ink and LTS to Develop Smart Patch to Improve Medical Management

Electronic ink technology provider E Ink Holdings and LTS have announced their partnership to develop a Smart Patch prototype.
23rd October 2017

LTS Announces New Address for Asia Office

LTS has announced that its Asia Office has moved to a new location in Shanghai, China. 
28th August 2017

IIS Receives First European Permit to Manufacture Microarray Patches

The German health authorities have granted LTS' whole-owned affiliate partner Innovative Injektions-Systeme (IIS) its first permit to manufacture transdermal microarrays and...
18th May 2017

LTS Progresses in Drug Serialisation

Serialisation, unique product identification (UPI), aggregation and Track ‘n Trace are some keywords describing various means and measures to prevent...
5th May 2017

LTS to Present at JP Morgan 35th Annual Healthcare Conference

LTS has announced that its CMO Dr Tim G Schlange will present at the JP Morgan 35th Annual Healthcare Conference.
3rd January 2017

LTS – Patient Oriented

Patient centricity is a key priority for today's pharmaceutical industry. The profound shift of meeting the expectations of ever better...
21st March 2016

Through the Skin

Transdermal systems are pharmaceutical patches that transport the active substances directly into the bloodstream through the skin – often with...
4th February 2016

Teva Launches ZECUITY® Migraine Patch

LTS congratulates its partner TEVA Pharmaceutical Industries for the US launch of ZECUITY®, a transdermal patch system for the treatment...
3rd September 2015

LTS Supports WHO and African Countries to Tackle River Blindness

River blindness (onchocerciasis) is a parasitic disease prevalent in 31 Sub-saharan Africa areas. If not controlled, it is a major...
12th November 2014
Quick Contact LTS Lohmann Therapie Systeme

Quick Contact LTS Lohmann Therapie Systeme
Quick Contact LTS Lohmann Therapie Systeme

Contact LTS Lohmann Therapie Systeme

Optional Data

Almost there, complete this form and hit the submit button to complete your registration.


Finally, complete a quick security check and confirm terms and conditions:

Quick Contact LTS Lohmann Therapie Systeme